Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Melinta Therapeutics, Inc.
Community-acquired bacterial pneumonia (CABP) is an acute infection of the pulmonary parenchyma with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea. The widespread emergence of antibiotic resistant pathogens, including the macrolide-resistant Streptococcus pneumoniae, has resulted in a need for new and effective antibiotics that have activity against CABP pathogens. Solithromycin is a fourth generation macrolide antibiotic with excellent activity against resistant S. pneumoniae and other key typical and atypical bacterial respiratory pathogens. A completed Phase 2 study showed comparable efficacy to levofloxacin in adults with CABP.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients ≥ 18 years of age
An acute onset of at least 3 of the following signs and symptoms (new or worsening):
1. Cough
2. Production of purulent sputum
3. Shortness of breath (dyspnea)
4. Chest pain due to pneumonia
At least 1 of the following:
1. Fever
2. Hypothermia
3. Presence of pulmonary rales and/or evidence of pulmonary consolidation
PORT Risk Class II, III, or IV
Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study
Not received any systemic antibiotics during the prior 7 days
You may not be if
Ventilator-associated pneumonia
Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease
Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms
Presence of known:
1. Viral or fungal pneumonia
2. Pneumocystis jiroveci pneumonia
3. Aspiration pneumonia
4. Other non-infectious causes of pulmonary infiltrates (e.g. pulmonary embolism, hypersensitivity pneumonia, congestive heart failure)